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Introduction
Leukotrienes (LTs) belong to a large family of lipid
mediators, termed eicosanoids, that are derived from
arachidonic acid (AA) and released from the cell mem-
brane by phospholipases. They can be found at high
levels in most inflammatory lesions and have been
shown to contribute to the physiological changes
observed during inflammatory responses. The first
step in the production of all LTs, the oxygenation of
AA to form 5-hydroperoxyeicosatretranoic acid and
the immediate dehydration of this unstable interme-
diate to LT A4 (LTA4), is carried out by 5-lipoxygenase
(5-LO). LTA4 produced from AA by 5-LO is the com-
mon substrate from which all LTs are formed. Metab-
olism of LTA4 by LTA4 hydrolase (LTA4-H) results in
the production of the potent chemoattractant LT B4
(LTB4). Alternatively, LTA4 can be conjugated with glu-
tathione by LTC4 synthase (LTC4-S) to produce LT C4
(LTC4) and its metabolites LTD4 and E4, collectively
referred to as the cysteinyl LTs. These lipid mediators
are known to increase vascular permeability and regu-
late smooth muscle tone.
The enzyme required for the initiation of produc-
tion of all LTs, 5-LO, is expressed predominantly by
cells of myeloid origin, particularly neutrophils,
eosinophils, monocytes/macrophages, and mast cells
(1–4). In contrast, the enzymes carrying out the sec-
ond step in LT biosynthesis, LTC4-S and LTA4-H, are
more broadly expressed, and high levels of LTA4-H
expression have been noted in several tissues (4, 5).
These findings have suggested that under some cir-
cumstances LTA4 produced by inflammatory cells can
be transferred to cells that express only LTA4-H, where
the synthesis of LTB4 is then completed.
Evidence suggesting that individual steps in the pro-
duction of eicosanoids might occur in different cells
comes, in part, from experiments showing that platelet-
derived arachidonate may be used by endothelial cells
to produce prostacyclin (6). The process was termed
“transcellular metabolism” or “transcellular biosyn-
thesis.” A number of lines of evidence support a role for
transcellular biosynthesis in the production of LTs.
First, labeling studies showed that, similar to the pro-
duction of prostacyclin, AA present in platelets could
be used by neutrophils to produce LTB4 (7). Thus, AA
used in the production of LTs can be provided by
neighboring cells and does not need to come only from
the activated myeloid cells. Furthermore, experiments
showing that LTA4 is released by activated polymor-
phonuclear leukocytes suggested that not only AA, but
also the metabolic intermediate LTA4, might be trans-
ferred between cells (8–10). Finally, results from a 
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number of coculture systems using purified popula-
tions of cells, tissues, and organs, are consistent with a
model in which at least a portion of LTs present in tis-
sue are produced by transcellular biosynthesis. In these
studies, the level and profile of the LTs produced from
individual cell populations were examined and com-
pared with those produced when two populations were
cultured together. These studies showed that both the
amount and type of LTs present in the supernatant
from the combined populations often differed from
that expected by simple addition of the LTs produced
by the individually cultured cells. For example, while
neutrophils stimulated with the ionophore A23187
produce primarily LTB4 and isolated lung tissue pro-
duces only very low levels of LTC4, coculture of lung tis-
sue with neutrophils resulted in a marked increase in
LTC4 production. Similar results were obtained from
coculture of neutrophils with either erythrocytes (11,
12), keratinocytes (13), alveolar macrophages (14), tra-
cheal cells (15), platelets (16–18), or endothelial cells
(19), or with (20) isolated organs, such as skin (13),
lung (21, 22), and heart (23).
Despite this intense investigation, it has not been
possible to determine whether transcellular biosyn-
thesis occurs in vivo and, if so, whether the levels of
eicosanoids produced by this pathway are sufficient
to contribute to the ongoing inflammatory response.
To examine this question directly we use two geneti-
cally engineered mouse lines; the first is deficient in
5-LO (5-Lo–/–), and the second is deficient in LTA4-H
(Lta4-h–/–). We and others have shown previously (24,
25) that the 5-Lo–/– mice fail to produce both LTB4 and
LTC4 and thus have blunted inflammatory responses
to peritoneal injection of zymosan A and to cuta-
neous application of AA (26). As expected, the Lta4-h–/–
animals are deficient in production of LTB4, while
biosynthesis of LTC4 remains intact and is not
decreased (27). The response of these mice to peri-
toneal injection of zymosan A and to cutaneous appli-
cation of AA is also attenuated (27). Using cells from
these two mouse lines and bone marrow chimeras
generated from these animals, we show that transcel-
lular metabolism can occur in vivo and that the LTs
produced may, in at least some instances, contribute
to an inflammatory response.
Methods
Mice. The generation of 5-Lo–/– and Lta4-h–/– mice has
been described previously (26, 27). These mutant alle-
les are maintained on a 129 genetic background of
129/Ola and 129/SvEv origin. All mice studied were at
least 8 weeks old. All experiments were approved by the
Institutional Animal Care and Use Committee.
Induction of LTB4 synthesis by freshly isolated peritoneal
leukocytes. Prior to the induction of peritonitis 
with zymosan A, animals were treated with a single
intravenous injection (10 mg/kg body weight) 
of indomethacin (Sigma-Aldrich, St. Louis, Mis-
souri, USA) to inhibit prostaglandin production. 
Zymosan A (Sigma-Aldrich) was suspended at 55°C
in sterile PBS to a final concentration of 1 mg/ml,
and 1 ml was injected into the peritoneal cavity.
Three hours later, mice were killed and the peritoneal
cavity lavaged with 4 ml of PBS. Lavage fluid (2
ml/mouse) was collected in polypropylene tubes on
ice, and cells were collected by centrifugation. Cell
pellets were washed in HBSS and resuspended in
HBSS at 107 cells/ml. Six hundred microliters of each
cell suspension was transferred to a 12-well plate.
After 5 minutes’ incubation at 37°C, cells were treat-
ed with A23187 (Sigma-Aldrich) for 30 minutes at
37°C. The media was then collected and frozen for
later measurement of LTB4 levels.
LTB4 detection. Proteins present in the media or
lavage fluid to be analyzed (500 µl) were precipitated
by addition of cold ethanol (2 ml), followed by cen-
trifugation at 15,000 g at 4°C for 10 minutes. The
supernatant was acidified with 8 ml of 0.1 M phos-
phate buffer, pH 3.5, and passed through an activat-
ed C18 column (Sep-Pak Plus; Waters Corporation,
Milford, Massachusetts, USA). The column was
washed twice and then eluted with ethanol/water
(90:10, vol/vol). The eluate was dried under nitrogen
and resuspended in ELISA buffer. LTB4 levels were
determined by ELISA (Cayman Chemical, Ann Arbor,
Michigan, USA).
Generation of bone marrow chimeras. Groups of six
female recipient mice were placed in a ventilated con-
tainer and exposed to 9 Gy at 80 cGy/min from a
cobalt source. Within 3 hours of irradiation of female
mice, male donors were killed and bone marrow cell
suspensions were prepared from femurs by repeated
flushing with 2 ml of PBS. Bone marrow cell suspen-
sions were filtered through Miracloth (22- to 25-µm
pores; Calbiochem-Novabiochem Corp., La Jolla, Cal-
ifornia, USA). Each female recipient received, by intra-
venous tail vein injection, the whole bone marrow cells
harvested from one male, resuspended in 0.5 ml of
saline. Transplanted mice were fed normal mouse
chow without antibiotic supplementation. To verify
that successful bone marrow reconstitution had
occurred, mice were anesthetized, and 100 µl of blood
was drawn from the orbital sinus and mixed with 700
µl of saline containing 1 mM EDTA. After centrifuga-
tion, cell pellets were resuspended in a specific buffer
for lysis of red blood cells and centrifuged again. This
process was repeated three times. The final pellet was
resuspended in PCR buffer with proteinase K and
incubated at 55°C for 1 hour. Proteinase K was inacti-
vated at 95°C for 10 minutes, and 3 µl of this prepa-
ration (about 1 µg DNA) was analyzed for the presence
of the Y chromosome by PCR using the following
primers designed to detect the Sry gene: 5′-TGTTCAGC-
CCTACAGCCACATG-3′ and 5′-CCACTCCTCTGTGA-
CACTTTAGCC-3′ (30 seconds at 94°C, 30 seconds at
56°C, and 90 seconds at 72°C for 30 cycles). Under
these conditions, a 340-bp fragment is amplified when
the blood sample contains male cells.
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Zymosan A–induced peritoneal inflammation. Peritoni-
tis was induced with zymosan A as described above,
except the peritoneal cavity was lavaged 3 hours later.
The lavage samples were centrifuged at 12,000 g at
4°C for 10 minutes and the supernatant stored at
–80°C until analysis.
AA induced cutaneous inflammation. Animals were
injected intravenously with indomethacin (10 mg/kg
body weight) and 0.5% Evans blue dye (10 ml of dye
solution per kilogram of body weight). Evans blue dye
(Sigma-Aldrich) was dissolved in PBS at pH 7.5. The
inner surface of the pinna of the left ear of each
mouse was painted with 20 µl of AA (100 µg/µl in ace-
tone), while the right ear was treated with an equal
amount of acetone alone. One hour after AA treat-
ment, mice were sacrificed, and an 8-mm-diameter
disc of tissue was punched from the center of each ear
and weighed. To extract the Evans blue dye, ear biop-
sies were incubated in 1 ml of formamide at 55°C for
48 hours. Serum protein extravasation was quantified
by measuring the absorbance of the formamide
extracts at 610 nm (A610).
Statistical analysis. Data are presented as the mean plus
or minus SEM. Log-rank test for survival analysis and
one-way ANOVA with Newman-Keul’s post test for
inflammatory responses analysis were performed using
GraphPad Prism version 3.00 for Windows (GraphPad
Software for Science Inc., San Diego, California, USA).
A P value of less than 0.05 was interpreted to denote
statistical significance.
Results
In vitro evidence for transcellular biosynthesis using 5-Lo–/–
or Lta4-h–/– cells. To determine whether mice deficient
in different enzymes required for the production of
LTB4 can be used to study the contribution of trans-
cellular metabolism to the production of LTs in vivo,
we tested whether leukocytes isolated from these
mouse lines can cooperate in the production of LTB4
in an in vitro assay. To obtain mouse leukocytes, we
elicited an inflammatory response by peritoneal
injection of zymosan A. Three hours after injection
of zymosan A, greater than 90% of the cells present in
the peritoneal lavage from these mice are neu-
trophils. Cells were treated with the ionophore
A23187 to stimulate the release of AA from the cell
membrane by phospholipase A2 and the subsequent
metabolism of this substrate into LTs. As expected,
no or barely detectable amounts of LTB4 were present
in the medium after treatment of either 5-Lo–/– or
Lta4-h–/– leukocytes with A23187 (Figure 1). In con-
trast, a significant increase in the LTB4 level was
measured in medium prepared from identically treat-
ed samples that consisted of a mixture of equal num-
bers of cells from 5-Lo–/– and Lta4-h–/– mice. The
results of this experiment are consistent with a model
in which the synthesis of LTs that is initiated in one
cell can be completed in neighboring cells after the
transfer of intermediate metabolites.
Generation of chimeric mouse lines. To determine whether
LTA4 produced by 5-LO in one cell can be metabolized
to LTB4 by the LTA4-H expressed in a different cell in
vivo, we used a model in which 5-LO–deficient mice are
irradiated and transplanted with bone marrow prepared
from wild-type mice or mice deficient in either 5-LO or
LTA4-H (Figure 2). The following bone marrow chimera
populations were generated from 5-Lo–/–, Lta4-h–/–, and
wild-type mice. First, we generated a population of mice
to control for the possible impact of irradiation 
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Figure 1
In vitro LTB4 production by leukocytes stimulated with A23187.
Leukocytes were isolated from peritoneal lavage fluid of mice in
which acute peritonitis had been induced by injection of zymosan A.
The 5-Lo–/– and Lta4-h–/– leukocytes do not produce significant
amounts of LTB4 in response to stimulation with A23187. In con-
trast, similar treatment of a mixture of these two cell populations
resulted in a significant increase in LTB4 production. This graph
shows data averaged from three separate experiments. *P < 0.01.
Figure 2
Description of the experiments. Chimeric mice are generated by
exposing mice to a lethal dose of ionizing radiation with subsequent
injection of donor bone marrow. The following chimeras were gen-
erated: wild-type mice receiving wild-type marrow (WT→WT), 
5-Lo–/– mice receiving wild-type marrow (WT→5-LO), 5-Lo–/– mice
receiving 5-Lo–/– marrow (5-LO→5-LO), and 5-Lo–/– mice receiving
Lta4-h–/– marrow (LTA4-H→5-LO). The callout illustration shows the
expected interaction between neutrophils of donor origin (top) and
the cells of recipient origin (bottom) that will lead to LTB4 produc-
tion. Labels in the illustration refer to the donors and to the recipi-
ents, respectively (donor genotype→recipient genotype). WT, wild-
type mice; LTA4-H, LTA4-H–deficient mice; 5-LO, 5-LO–deficient
mice; AA, arachidonic acid.
treatment on the mice and/or changes in hematopoiet-
ic cell populations in reconstituted animals on the
inflammatory response of the mice. This population
consisted of wild-type 129 mice reconstituted with bone
marrow cells isolated from other wild-type animals
(WT→WT). A second control population was generat-
ed by irradiation of 5-Lo–/– mice followed by reconstitu-
tion with 5-Lo–/– bone marrow (5-LO→5-LO). This pop-
ulation served as a control for possible changes in the
dependence of various inflammatory responses on LTs
after the irradiation and reconstitution treatment pro-
tocol in the deficient mice. Two experimental popula-
tions of bone marrow chimeras were generated. One
group was generated by irradiation of 5-LO–deficient
mice and reconstitution of these mice with wild-type
bone marrow (WT→5-LO). These animals allowed us to
measure the contribution of LTs derived from
hematopoietic cells to the inflammatory response. For
the other experimental group, we irradiated 5-Lo–/– mice
and reconstituted these animals with bone marrow
from Lta4h–/– animals (LTA4-H→5-LO). We expected
that the resulting chimeras would have myeloid popu-
lations capable of producing LTA4, but that, because of
the lack of LTA4-H, no LTB4 could be produced without
cooperation between these cells and cells of the recipi-
ent animal (Figure 2a, right panel).
Wild-type mice (n = 11) exposed to 9 Gy of ioniz-
ing irradiation died 8–15 days after treatment (data 
not shown). When the mice received bone marrow 
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Figure 3
Efficiency of bone marrow transplantation. (a) Survival curve
obtained after irradiation and reconstitution with marrow from var-
ious genotypes. Symbols refer to the donors and to the recipients,
respectively (donor genotype→recipient genotype). WT, wild-type
mice; LTA4-H, LTA4-H–deficient mice; 5-LO, 5-LO–deficient mice. (b)
PCR detection of the Y chromosome in total DNA extracted from
blood of female mice transplanted with marrow from male donors.
Lane 1 shows expression of the Y chromosome as a 340-bp band
detected in blood from a male control. Lane 2 was loaded with DNA
from a nontransplanted female. Other lanes were loaded with DNA
from transplanted females.
Figure 4
Transcellular biosynthesis in vivo. (a) Zymosan A–induced peri-
toneal inflammation. LTB4 production was measured in the peri-
toneal lavage fluid. Loss of 5-LO expression impairs LTB4 produc-
tion in response to zymosan A stimulation (5-LO→5-LO). In
contrast, the presence of leukocytes expressing 5-LO, but unable to
produce LTB4 (LTA4-H→5-LO), results in LTB4 production. 
*P < 0.05. WT, wild-type; 5-LO, 5-LO–deficient mice; LTA4-H,
LTA4-H–deficient mice. The transplanted groups are identified as
donor→recipient genotypes. Results are presented as numerical
values in Table 1. (b) Acute cutaneous inflammatory responses to
AA. Mice received Evans blue dye and indomethacin immediately
before topical application of AA. At 1 hour after the treatment, the
inflamed tissue was biopsied, weighed, and the serum exudate pres-
ent in the tissue was determined. The white bars represent the dif-
ference in optical densities (∆ OD) between the ear treated with AA
and the ear treated with vehicle (acetone) alone. The black bars
represent the difference in ear-disc weights (∆ ear weight) between
the AA-treated ear and the vehicle-treated ear for each mouse.
While loss of 5-LO or LTA4-H attenuated the inflammatory
response to AA, the response was significantly increased in mice in
which the reconstituted immune cells express 5-LO, but are unable
to produce LTB4 (LTA4-H→5LO). This graph combines data from
two separate experiments. Statistical significance is indicated only
for the transplanted groups for clarity. *P < 0.05. WT, wild-type; 
5-LO, 5-LO–deficient mice; LTA4-H, LTA4-H–deficient mice. Results
are presented as numerical values in Table 1.
transplants within 6 hours after exposure to the irradi-
ation, most (80%) of the animals survived and
remained healthy for over 3 months (Figure 3a);
although there was a slightly lower survival of the
LTA4-H→5-LO population, this difference did not
reach statistical significance (P > 0.05). This finding is
consistent with the successful engraftment of the bone
marrow and reconstitution of the immune system and
was true for all chimeras generated from wild-type,
5-Lo–/–, and Lta4-h–/– mice (log-rank test: P = 0.26).
Because the bone marrow used for transplantation was
prepared from male mice, and in all cases the recipient
animals were females, PCR amplification of DNA
sequences specific to the Y chromosome was used to
monitor reconstitution of the irradiated mice with
donor hematopoietic cells, as shown in Figure 3b.
LTB4 production in Lta4-h–/–/5-Lo–/– bone marrow
chimeras. Zymosan A is a purified polysaccharide frac-
tion of yeast cell wall that elicits a strong inflamma-
tory response when introduced into the peritoneal
cavity. This response is characterized by an influx of
neutrophils by 2 hours, and a measurable increase in
LTB4 biosynthesis at 3 hours, which mainly is due to
the infiltration of the phagocytic cells. The level of
LTB4 production in peritoneal lavage fluid in
response to zymosan A was shown previously to be
dramatically decreased in Lta4-h–/– mice (27). We there-
fore used this model to determine whether measura-
ble levels of LTB4 could be produced by transcellular
metabolism in vivo.
As shown in Figure 4a and Table 1, peritoneal lavage
fluid obtained from wild-type mice treated with
zymosan A contained high levels of LTB4. As expect-
ed, LTB4 levels were barely detectable in the lavage
fluid obtained from similarly treated 5-Lo–/– mice
reconstituted with 5-Lo–/– marrow. In contrast, LTB4
production was restored in the 5-Lo–/– mice reconsti-
tuted with wild-type bone marrow, supporting the
hypothesis that the majority of LTB4 is produced by
the neutrophilic infiltrate characteristic of this
inflammatory response. The 5-Lo–/– mice transplant-
ed with Lta4-h–/– marrow produced more LTB4 than
the 5-Lo–/– mice grafted with syngenic marrow. These
data suggest that LTB4 production increased signifi-
cantly when donor LTA4-H–deficient leukocytes,
which are able to generate LTA4
but not convert it to LTB4,
encountered 5-LO–deficient
but LTA4-H–sufficient recipient
cells in their vicinity.
Cutaneous inflammatory response
to AA in Lta4-h–/–/5-Lo–/– bone mar-
row chimeras. We next sought to
determine whether transcellular
metabolism could produce suf-
ficient LTB4 to significantly con-
tribute to the physiological
changes observed during an
inflammatory response. We
have shown previously that 5-LO– and LTA4-H–defi-
cient mice have an attenuated inflammatory response
to cutaneous application of AA (25–27). When these
mice are treated with the cyclooxygenase inhibitor
indomethacin to block the production of
prostaglandins, both the edema formation and influx
of neutrophils characteristic of the response are almost
entirely dependent on LT production.
To test the ability of the different mice generated to
mount an inflammatory response to topical applica-
tion of AA on ear tissue, we measured both the weight
of ear biopsy samples and the extravasation of plasma
fluid (as represented by extravasation of Evans blue
dye, which binds to serum proteins). In addition to
the four groups of bone marrow chimeras, wild-type
mice and 5-LO– and LTA4-H–deficient mice were
included in the study.
As can be seen in Figure 4b and Table 1, application
of AA to the pinna of the ear of wild-type 129 mice led
to a dramatic change in ear weight that was accompa-
nied by increased protein extravasation into the tissue.
A response of similar magnitude was elicited in the
wild-type mice reconstituted with isogenic bone mar-
row (compare WT with WT→WT). This finding sug-
gests that the treatment of mice with irradiation, fol-
lowed by bone marrow reconstitution, did not
significantly alter the ability of mice to respond to AA.
Similar to our previous results, the inflammatory
response to cutaneous application of AA was signifi-
cantly attenuated in the 5-Lo–/– mice (compare 5-LO
with WT). These data are consistent with earlier stud-
ies showing that in indomethacin-treated animals this
inflammatory response is dependent on the produc-
tion of LTs by the 5-LO pathway. The dependence of
this response on expression of 5-LO was also observed
in the 5-Lo–/– mice that had been irradiated and recon-
stituted with syngenic bone marrow (compare 5-LO
with 5-LO→5-LO). We reported previously that edema
and plasma protein extravasation after topical applica-
tion of AA is reduced considerably in mice lacking
LTA4-H, demonstrating the LTB4 contribution to this
response (27). Consistent with our previous results, the
inflammatory response was significantly attenuated
in mice deficient in expression of LTA4-H, although
not to the low levels observed in the 5-LO–deficient
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Table 1
Numerical data obtained from experiments demonstrating the transcellular biosynthesis in vivo
Ear ∆ weight Ear ∆ OD Peritoneal LTB4
(gram) (absorbance units) (picogram/milliliter)
WT 21.1 ± 1.23 (n = 9) 0.717 ± 0.070 (n = 8)
5-LO 1.81 ± 0.87 (n = 7) 0.055 ± 0.025 (n = 6)
LTA4-H 2.93 ± 0.93 (n = 10) 0.131 ± 0.024 (n = 10)
WT/WT 20.0 ± 1.53 (n = 10) 0.670 ± 0.058 (n = 10) 3,040 ± 299 (n = 6)
5-LO/5-LO 1.54 ± 0.54 (n = 12) 0.060 ± 0.015 (n = 12) 51.5 ± 11 (n = 8)
LTA4-H/5-LO 9.25 ± 2.41 (n = 13) 0.336 ± 0.089 (n = 13) 630 ± 88 (n = 7)
WT/5-LO 9.59 ± 1.53 (n = 11) 0.294 ± 0.046 (n = 11) 3,420 ± 38 (n = 5)
animals (compare LTA4-H with WT). The response
remaining in these mice is likely due to the continued
production of LTC4 by the LTA4-H–deficient mice.
These findings indicate that the increase in ear weight
and edema formation is largely dependent on the pro-
duction of LTB4 and recruitment of leukocytes to the
site of inflammation. The defective response of the 
5-LO–deficient mice was partially corrected by recon-
stitution of the hematopoietic system with bone mar-
row from congenic wild-type animals (compare 
5-LO→5-LO with WT→5-LO). However, this
response remained less vigorous than that observed
in the wild-type animals. Transplantation of the 
5-LO–deficient mice with bone marrow from LTA4-H–
deficient mice also restored, in part, the ability of
these mice to respond to AA (compare 5-LO→5-LO
with LTA4-H→5-LO).
Discussion
Previous studies have suggested a model in which the
profile and level of eicosanoids produced during an
inflammatory response reflect, in part, the cooperation
between myeloid and nonmyeloid cells in their biosyn-
thesis. However, direct proof that transcellular biosyn-
thesis of LTs occurs in vivo has been difficult to obtain.
We show here the utility of using bone marrow
chimeras and genetically modified animals to address
this question. While neither Lta4-h–/– nor 5-Lo–/– animals
produce LTB4, this LT can be detected in bone marrow
chimeras generated from these two mouse lines. Fur-
thermore, we show that LTB4 produced by transcellu-
lar biosynthesis can restore the ability of the mice to
mount an inflammatory response to AA.
Production of LTB4 by transcellular biosynthesis was
examined after induction of peritonitis in the bone mar-
row chimeras with zymosan A. Zymosan A is known to
elicit an inflammatory response characterized by infil-
trates composed primarily of neutrophils within 3–6
hours after treatment. Previously, we showed that while
zymosan A–induced peritonitis is characterized by high
levels of LTB4 in wild-type mice, LTB4 could not be
detected in lavage fluid from Lta4-h–/– mice. Because of
the high levels of LTB4 that can be measured in this
response, we chose this system to determine whether, in
this particular inflammatory response, LTA4 produced
by neutrophils could be transferred to other cells for fur-
ther metabolism into LTB4. Bone marrow chimeras were
generated in which the majority of the hematopoietic
cells express 5-LO but not LTA4-H. Neutrophils normal-
ly do not produce significant amounts of LTC4 because
of low levels of LTC4-S. Thus, upon stimulation of the
neutrophils, LTA4 is produced but is likely to accumu-
late in these LTA4-H–deficient cells. In these bone mar-
row chimeras, nonmyeloid cells are unable to metabolize
AA into LTA4 because they do not express 5-LO. Howev-
er, these cells express LTA4-H. If the LTA4 produced by
the neutrophils is transferred to these cells, then we
would expect to observe LTB4 in the lavage fluid. We
report here that this transcellular biosynthesis does
occur and can produce about 20% of the LTB4 levels
observed when the reconstituted population of cells
express both 5-LO and LTA4-H.
The production of LTB4 by transcellular biosynthesis
in the bone marrow chimeras, however, might be an
overestimate of the contribution of this pathway to
LTB4 production in wild-type mice for the following
reason. LTA4 might never accumulate in wild-type neu-
trophils because of its rapid conversion by LTA4-H
present in the same cell. Thus, the production of LTB4
by transcellular biosynthesis we observed might be
unique to this experimental system. Conversely, the
amount of LTB4 produced by transcellular biosynthe-
sis might be very dependent on the ratio of inflamma-
tory cells to nonhematopoietic cells and the level of
LTA4-H in these acceptor cells. It is possible that, in this
model of peritonitis, a high ratio of inflammatory cells
to parenchyma cells reduces the contribution of the
transcellular metabolic pathways to the overall pro-
duction of the LTs. Furthermore, we cannot rule out
the possibility that some of the LTB4 we have measured
in the LTA4-H→5-LO chimeras is the result of tran-
scellular biosynthesis between neutrophils of donor
and recipient origin. While our data clearly show that
the donor bone marrow cells have engrafted, some sur-
vival and eventual contribution of the recipient
hematopoietic cells is possible. Thus, a small percent-
age of the neutrophils might be 5-LO deficient and
LTA4-H sufficient. These cells could contribute to the
production of the observed LTB4. However, even if this
were the case, our measurement of LTB4 clearly shows
that transcellular metabolism can occur during an in
vivo inflammatory response.
To determine whether LTs produced by transcellu-
lar biosynthesis could contribute to an inflammato-
ry response, we used the AA-induced model of cuta-
neous inflammation. While AA is not a physio-
logically relevant inflammatory stimulus, this model
has several characteristics that made it ideal for these
initial in vivo studies. In this model, the contribution
of LTs to the inflammatory response can be isolated
by pretreatment of the mice with indomethacin, a
cyclooxygenase inhibitor. After treatment with
indomethacin, 5-LO–deficient mice fail to respond to
AA. In addition, we have shown previously that the
response to AA of mice deficient in LTA4-H is blunt-
ed (27). Furthermore, we show here that when the
LTA4-H–deficient mice are treated with indo-
methacin, edema formation and increases in ear
weight in response to AA are not significantly greater
than that observed in the 5-LO–deficient animals.
To carry out these experiments, it was first necessary
to determine the extent to which cells of hematopoi-
etic origin contributed to AA-induced cutaneous
inflammation. This was done by comparing the
inflammatory response in wild-type mice reconstitut-
ed with wild-type bone marrow (WT→WT) with the
inflammatory response observed in 5-LO–deficient
mice reconstituted with wild-type bone marrow
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(WT→5-LO). We were surprised to find that plasma
protein extravasation and changes in tissue weight in
response to AA in mice in which the parenchyma cells
were 5-LO deficient (WT→5-LO) were only about half
of that observed in wild-type mice (WT→WT). Two
explanations for this observation are possible. First,
cells of nonhematopoietic origin might contribute to
this response. Some evidence supporting this possi-
bility comes from in vitro culture studies in which pro-
duction of LTs from keratinocytes was demonstrated
(28). Alternatively, some recovery of the recipient
hematopoietic cells might have occurred; therefore, at
least a small portion of the hematopoietic cells is 5-LO
deficient and unable to produce LTs. However, the
observation that the level of LTB4 in the lavage fluid of
the LTA4-H→WT and WT→WT chimera is similar
(and production of this mediator has been attributed
to the recruited neutrophils) suggests that the major-
ity of the myeloid cells are of donor origin. This would
be consistent with the former hypothesis, namely that
some nonhematopoietic cells can produce LTs. Future
experiments that monitor not only engraftment but
also survival of recipient marrow should allow us to
further rule out the possibility that the decreased
inflammatory response observed in the 5-LO–defi-
cient mice reconstituted with wild-type marrow can be
attributed to residual 5-Lo–/– myeloid populations.
Irradiation and subsequent reconstitution of 
5-LO–deficient mice with LTA4-H–deficient marrow
(LTA4-H→5-LO) resulted in dramatic increases in
inflammation as compared with 5-LO–deficient mice
reconstituted with syngenic marrow (5-LO→5-LO).
Although the synthesis of LTB4 is not specifically meas-
ured in the cutaneous model, the increased response in
the LTA4-H→5-LO group probably results from LTB4
produced by transcellular conversion of LTA4. It is
unlikely that the response in these mice is due to pro-
duction of LTC4 by the hematopoietic cells because the
response of the LTA4-H→5-LO mice is significantly
higher than that observed in the LTA4-H–deficient
mice. The loss of LTA4-H has a large impact on edema
formation in this model despite that fact that cells defi-
cient in this enzyme, which express 5-LO and LTC4 syn-
thase, can still produce LTC4 and subcutaneous injec-
tion of LTC4 can itself induce edema formation. This
suggests that there is significant synergy between the
two classes of LTs, LTB4 and the cysteinyl LTs, in this
response. It should be possible to test this in the future
with the development of mice deficient only in the pro-
duction or response to LTC4. We cannot exclude the
possibility that increased lipoxin production resulting
from shunting into this pathway contributes to the
decreased edema seen in the LTA4-H–deficient mice
(29). Conversely, we cannot rule out the possibility that
the restoration of the response in the chimeras
(LTA4→5-LO) is due not only to production of LTB4 by
transcellular metabolism, but in part reflects alter-
ations in lipoxin production, for example lower levels
of lipoxins in the LTA4-H→5-LO versus LTA4 mice.
LTs are potent mediators of inflammation and are
capable of inducing all of the cardinal signs of inflam-
mation. LTB4 is one of the most potent chemoattrac-
tants for neutrophils, and LTC4, originally identified
as the slow-reacting substance of anaphylaxis, is one
of the most potent activators of contraction of airway
smooth muscle identified to date and is also a potent
vasoconstricting agent. It is, therefore, perhaps not
surprising that the production of these lipid media-
tors is tightly regulated and that it is generally limit-
ed to inflammatory responses. The transcellular
biosynthesis of LTs might provide an important
mechanism for regulating the production of these
lipid mediators during an inflammatory response.
The absence of 5-LO expression in tissues protects the
organism from the production of these lipids, but
also limits the levels of LTs that can be produced in
the early minutes of the inflammatory response.
Transcellular biosynthesis might provide a means for
maximizing the production of LTs from recruited
myeloid cells. Excess LTA4 produced by these cells
could be metabolized into active lipid mediators, not
only by LTA4-H in the myeloid cell itself, but also by
adjacent cells in the inflamed tissue.
The studies reported here provide direct evidence
that transcellular biosynthesis contributes in vivo to
the production of LTB4 in two experimental models of
inflammation: zymosan A–induced peritonitis and
AA-stimulated cutaneous inflammation. Future stud-
ies using bone marrow chimeras generated from 
5-Lo–/–, Lta4-h–/–, and Ltc4-s–/– mice should allow the role
of transcellular biosynthesis to be studied in other
inflammatory responses and to be extended to the
production of other LTs, such as LTC4.
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